Yes they can begin to sell after approval following a phase III. The Phase IV is when the FDA asks the company to continue to collect data often on potential side effects after approval. They also look for more information on optimal dosing or other possible indications for use. Because so many more people are expected to use the drug after approval they will be able to get better data. Also the restrictions on who can participate in the clinical trials will be lifted so they will have a wider variety of patients
Shiller is an economics professor at Yale who just won the economics prize in honor or Alfred Nobel this last year. He is credited for his analysis of housing and forewarned the housing bubble we just went through --if you buy property his Shiller Index of property value is one to watch.
BIIB has been very volatile these days. Has always tended to go up before the news and drop after its released. Long term its still going to climb
BIIB still has lots of upside with three drugs now in line for FDA approval. Those who short this stock are asking for a whole lot of financial loss--you have way more to lose by shorting than by investing even at these levels. I can see a 50 point gain by the end of the year so IMO its not to late to get in.
PML is under control with the test to detect JCV. Remember anyone who is positive for JCV should think twice about ANY--I will say it again-- ANY immune suppressor not just the ones made by BIIB. Oral drugs are what people want and BIIB's oral drug sales in on month have exceeded the #$%$ Novartis put on the market in a year.
I agree take SOME profit if thats what you want--but don't cash it all in this stock will keep growing. There is a good pipeline here and more things coming up for approval over the next year.
For those who have trouble getting insurance to pay for Tecfidera remind them its a FDA approved drug not experimental any longer Also contact BIIB they have a great patient advocacy group that could help. I expect that demand will grow over time as will the willingness of insurance companies to pay for it.
Why is it there are so many idiotic replies to posts to someones report and not to people who want to discuss anything of interest. The repeated --"great report" or "worth it" just shows how brain dead people all are. Of course its likely they are nothing but fake accounts.
I really miss the good old days where we got real information about what was going on from the inside of the company and some interesting discussions.
Be ready for next Thursday when the FDA announces its decision on BG-12
Are there any real people out there anymore?
Could not agree more--I was in favor of a split last year at this time. 2 for 1 is good 3 for 1 is better. I think a split would drive the price up even more.
Rumors of another round of layoffs in the mix.
Does this mean Immunology will go the way of Oncology? Will unproductive projects be slashed along with the people who work on them? Could it be a pruning of dead wood? Maybe just a focus on new projects and bringing in new blood that could be very fruitful for BIIB and its shareholders.
All of the above?
I would also like to see a split--maybe 1:2 or 1:3--I think 1:4 is a little to much. The parent company Biogen (BGEN) split twice (1:2 each time) in the past at prices lower than this. This was before they merged with Idec and became BIIB.
Even with some companies getting prices at higher levels (Apple and Google for example) the Biotechs don't seem to go that high. I would buy even more shares if there was a split. There is potential for good things coming with this company so there would be more upside if there was a split. Until then i think i can make more $$ on other stocks.
You should have done your own homework--its been obvious for some time this was a high risk stock. The clinical trials have been a big bust so far. The news was easy to find. Sure if a miracle happened and the third trial turned out different you might have made some money but know the risk you are taking.
If you buy anything only on a brokers recommendation your a fool I am sure they were happy to unload this POS on you.
Scangos has downsized the pipeline as well.
For Scangos it's all about having BIIB in a good position for a take over. He's will make some good cash over the next two years as he completes Carls marching orders.
At this point lets hope Carl gets some big $$$ for BIIB. Then we all benifit.
The people in San Diego were right to be worreid when they were--BIIB sold the Nobel site and lied when they said they would relocate to another site in San Diego---there is no more BIIB in San Diego.
the Oncology TA were right to be worried when they were--now there is no more Oncology.
time to pay attention
some selected Scangos quotes From the Boston Globe article on 10/06/10
By the end of the year, George A. Scangos, who arrived at Weston-based Biogen Idec in July, will unveil an operating blueprint calling for intensifying the focus on some drug programs while deemphasizing — or even selling off — others and accelerating the pursuit of drug development partnerships with other companies.
“I don’t think we should dabble,’’ Scangos, 62, said in his first interview as chief executive. “If we’re going to be in an area, I think we ought to do it with enough expertise and power and resources to be competitive and be among the leaders in that area.’’
Biogen Idec’s portfolio and pipeline of drugs are concentrated in neurology, immunology, oncology, hematology, and generic medicines. Scangos said it is too soon to specify which could be spun off, though he suggested the company might expand work in neurology, where it is a leader in multiple sclerosis therapies.
As the MS field becomes more competitive — Swiss drug maker Novartis AG won US approval last month for the first oral treatment — Scangos said Biogen Idec, which is in late-stage development with its own MS pill, also could target other neurological disorders, such as Parkinson’s or Lou Gehrig’s diseases.
Blockbuster drugs, those generating at least $1 billion a year in sales, are — for obvious reasons — coveted. Biogen Idec has three: Avonex and Tysabri for MS, and Rituxan for non-Hodgkin lymphoma. Scangos, however, said he would like to introduce a “more focused mentality’’ at the company, pressing forward into personalized medicine, where drugs can be designed for population subsets.
Scangos promised to work aggressively to boost shareholder value at Biogen Idec, the state’s second-largest biotechnology company. But he acknowledged he is “not particularly concerned’’ about whether it might eventually be bought by a larger drug maker.
“I can’t tell you we’ll be here five years from now,’’ he said. “But we’re not working actively towards not being here five years from now. We’re working actively to build the company.’’
“If you’re struggling on multiple fronts, you have to rein it in,’’ said Joshua Schimmer, managing director at the health care investment bank Leerink Swann in New York. “Biogen doesn’t look like it’s struggling at this point, but in some of their areas they don’t have critical mass.’’
Schimmer said he wasn’t surprised Scangos can’t commit to keeping the company independent. “That’s a reasonable position,’’ he said, citing the appetite of Icahn and other large investors to generate money by spinning off businesses. “Any company that has the shareholders that Biogen Idec has can’t be in the position to say whether they’ll be stand-alone five years from now.’’
Scangos said he has spent much of the past two months talking to employees, visiting company sites in Massachusetts, North Carolina, and California, taking stock of research and development programs, and rethinking strategy.
“The company’s done a lot of good things over the years,’’ he said. “It’s one of the most successful biotechnology companies in the world. We can do better.’’
Scangos said he also would like to see Biogen Idec become the “partner of choice’’ for small biotechnology companies while also expanding collaborations with academic research labs and large pharma companies in the region.
“We do good research here,’’ he said. “But if you look at the totality of all the research that’s directed against the diseases in which we’re interested, we do a small fraction of that. We’re a very tiny circle in the middle of this big universe. So it’s more likely interesting advances will come from outside the company than within the company.’’